As new immunotherapy drugs hope to turn metastatic cancer into a chronic manageable condition, or at least significantly prolong life in the near term, investors are understandably excited about their potential.

And one company at the forefront of this move, Bristol-Myers Squibb, just got a huge upgrade today from Wall Street titan Citigroup, sending shares 5% higher. Citi moved Bristol from "neutral" to "buy" and upped its old $33 price target to $55 per share.

In this video, health-care analyst David Williamson discusses Bristol's big upgrade and gives a few of his key takeaways from the report.

Follow David on Twitter: @MotleyDavid.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.

The Motley Fool owns shares of Citigroup. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.